Actively Recruiting
Open-label Study of PHST001 to Assess Safety and Antitumor Activity in Adults with Advanced Solid Tumors
Led by Pheast Therapeutics · Updated on 2026-10-05
426
Participants Needed
20
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of PHST001, an anti-CD24 macrophage checkpoint inhibitor, in adults with advanced relapsed or refractory solid tumors. This first-in-human, open-label Phase 1a1b study includes patients with various solid tumors, including CNS tumors in Phase 1a, and several tumor-specific cohorts in Phase 1b. The goal is to find a recommended dose and evaluate the treatment alone or combined with other anticancer therapies. Participants will receive PHST001 either as monotherapy or combined with standard anticancer drugs such as paclitaxel, topotecan, doxorubicin, FOLFIRI, FOLFOX, gemcitabine, mirvetuximab soravtansine, or trastuzumab deruxtecan. Dosing occurs every three weeks, with Phase 1a focusing on dose escalation to identify safe dosing levels. Phase 1b includes tumor-specific groups and randomized cohorts evaluating combinations. Some participants may be randomized to receive mirvetuximab soravtansine alone or with PHST001. Throughout the study, participants are closely monitored with safety assessments for adverse events, dose-limiting toxicities, and serious events up to 90 days post-treatment. Tumor response and progression are evaluated using RECIST or RANO criteria for up to two years. Pharmacokinetic parameters such as serum concentration and clearance of PHST001 are also measured. The study lasts until 2031, with ongoing assessments during treatment and follow-up periods.
CONDITIONS
Brief Title
A Study of PHST001 in Advanced Solid Tumors
Research Team
R
Raphaël Rousseau, Chief Medical Officer, PhD, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here